Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Gomez, C. Taillé, R. Lazor, B. Crestani, V. Cottin, M. Reynaud-Gaubert (Marseille, Paris, Lyon, France). Prolonged sirolimus therapy in advanced pulmonary lymphangioleiomyomatosis; a multicenter French experience. Eur Respir J 2012; 40: Suppl. 56, 1776

Member's Comments

No comment yet.

Related content which might interest you: Concomitant corticosteroid with anti-fibrotic therapy for idiopathic pulmonary fibrosis: a prospective multicenter study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Intravenous cyclophosphamide therapy for patients with interstitial pulmonary disease associated with collagen vascular disorders. A single-center experience Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Long-term sirolimus treatment in lymphangioleiomyomatosis Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases Year: 2019 CompERA-XL: International, prospective registry for the documentation of first-line and maintenance therapy in patients with pulmonary hypertension Source: Annual Congress 2010 - Pulmonary hypertension Year: 2010 Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicentered open-label study Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study Source: Eur Respir J 2014; 43: 1691-1697 Year: 2014 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial Source: Eur Respir J 2016; 47:1452-1460 Year: 2016 Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis Source: Eur Respir Rev 2015; 24: 58-64 Year: 2015 Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension Source: Eur Respir J, 57 (1) 2001120; 10.1183/13993003.01120-2020 Year: 2021 PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients Source: International Congress 2016 – IPF clinical Year: 2016 Early-onset therapy with sirolimus helps to improve prognosis of patients with lymphangioleiomyomatosis (LAM) Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases Year: 2019 Multi-institutional prospective cohort study of prognostic factors in patients with idiopathic pulmonary fibrosis receiving long-term oxygen therapy. Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Belgian prospective, multicenter, observational study of patients with malignant pleural mesothelioma treated with pemetrexed plus platinum Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma Year: 2014 Real-life data on the safety and tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) patients: A single-centre retrospective study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Effect of bosentan on MMP-7 levels as add-on therapy in idiopathic pulmonary fibrosis. A prospective study Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Long-term outcome of sarcoidosis-associated pulmonary hypertension in the modern treatment era Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021 Upfront combination therapy in the treatment of scleroderma-associated pulmonary arterial hypertension: Results of an open label trial Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Safety of corticosteroid therapy in patients with pulmonary sarcoidosis Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017